OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study ...
OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® cancer vaccine in second-line NSCLC, authorized in 14 countries. The trial aims to confirm Tedopi®'s therapeutic benefit in metastatic cancer patients, with presentations at the 2024 World Conference on Lung Cancer and the European Society for Medical Oncology congress.
Reference News
OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.
OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® cancer vaccine in second-line NSCLC, authorized in 14 countries. The trial aims to confirm Tedopi®'s therapeutic benefit in metastatic cancer patients, with presentations at the 2024 World Conference on Lung Cancer and the European Society for Medical Oncology congress.